Bill's stock bounces after denial of report it was pursuing a $2 billion cash-and-stock buyout of Melio Payments
Shares of Bill Holdings Inc. (BILL) bounced off a 3 1/2-year low in morning trading Thursday, after the financial software broke from tradition to deny a "market rumor." The stock had tumbled as much as 16.5% earlier to an intraday low of $51.94, the lowest price seen since April 27, 2020, after Bloomberg reported late Wednesday that the company was near a deal to digital payment tools provider Melio Payments in a cash-and-stock deal valued at $1.95 billion. On Thursday, Bill said that while it's general policy is not to comment on market rumors or media speculation, "Bill is not pursuing any such acquisition at this time." The stock was last down 10.1%. The stock's current selloff follows a 25.2% plunge last Friday, after the company beat fiscal first-quarter earnings expectations but provided a downbeat full-year outlook, saying inflation and consumer uncertainty was posing a bigger threat to smaller-business customers. The stock has tumbled 48.1% over the past three months while the S&P 500 has eased 2.1%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-09-23 1052ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks